ChemoTech has signed a distribution agreement with Lambertis Corporation SA "Lambertis" in Chile, which means that ChemoTech is now going to start the process of introducing the IQwave(TM) and its TSE technology to the first country in South America. Chile, with its approximately 19.631.721 inhabitants (2023), has a well-developed health care system and insurance scheme where currently, 68% of the population is covered by the public fund and 18% by private companies. Cancer is the second leading cause of death and Chile has an adjusted incidence rate of 226 per 100,000 in men and 180 per 100,000 in women.

Every year approximately 51,600 new cases are being diagnosed (excluding non-melanoma cancer). In Chile the old and static electroporation devices were introduced 2012, by the same entrepreneur, Patricio Fajardo, that owns Lambertis. This means that even if Lambertis is an entrepreneurial driven company it has a long track record of introducing medical devices in the cancer field.

They have a wide network and close collaborations with KOLs (Key Opinion Leaders) in Chile. The Distribution agreement signed today includes ChemoTech's IQwave TSE system for Human Care. Mr. Fajardo used to work as a distributor to the famous Swedish company Elekta.

He started his collaboration with Elekta in 2002 and became part-owner of a Gamma Knife unit in Santiago in 2010 following an introduction of Göran Hellers, the late co-founder of ChemoTech. ChemoTech will aim to place one (1) IQwave at an oncology hospital in Chile by the end of the fourth quarter of 2023 or 1st quarter 2024, depending on the process time for the registration.